1. Home
  2. BFS vs ABUS Comparison

BFS vs ABUS Comparison

Compare BFS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BFS

Saul Centers Inc.

HOLD

Current Price

$34.28

Market Cap

809.1M

Sector

Real Estate

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.37

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFS
ABUS
Founded
1993
2005
Country
United States
United States
Employees
98
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
809.1M
848.8M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
BFS
ABUS
Price
$34.28
$4.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$44.00
$5.00
AVG Volume (30 Days)
41.2K
1.7M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
6.92%
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
$0.30
N/A
Revenue Next Year
$5.67
$239.71
P/E Ratio
$30.48
$5.10
Revenue Growth
N/A
128.21
52 Week Low
$29.16
$3.04
52 Week High
$35.45
$5.10

Technical Indicators

Market Signals
Indicator
BFS
ABUS
Relative Strength Index (RSI) 56.81 50.92
Support Level $32.56 $4.17
Resistance Level $34.99 $4.60
Average True Range (ATR) 0.77 0.16
MACD -0.00 0.01
Stochastic Oscillator 67.74 61.46

Price Performance

Historical Comparison
BFS
ABUS

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: